Marcus Maurer

Mar 4, 2024 | healio.com | Richard Gawel |Kristen Dowd |Marcus Maurer

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Barzolvolimab is an anti-KIT monoclonal antibody, and mast cells need KIT to survive. Weekly hive and itch scores fell with treatment. There were no serious adverse events related to the drug.

Nov 21, 2023 | healio.com | Alexandra Sasha Todak |Kristen Dowd |Marcus Maurer

You've successfully added Allergy/Asthma: Skin Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:More patients assigned remibrutinib vs. placebo showed improvements in UAS7, ISS7 and HSS7.

May 19, 2023 | mdpi.com | Jonathan Bernstein |Ana Giménez-Arnau |Marcus Maurer |Petra Staubach

Open AccessArticlebyJonathan A. Bernstein 1,*, Ana Giménez-Arnau 2, Marcus Maurer 3,4, Petra Staubach 5, Nathalie Barbier 6, Eva Hua 7, Thomas Severin 6, Pedro A.